Artemis Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ATMS research report →
Price Chart
About the company
Artemis Therapeutics Inc. currently lacks substantial business operations. Situated in New York, New York, this company previously concentrated on developing pharmaceutical agents to prevent and treat severe and life-threatening infectious diseases.
- CEO
- Shimon Citron
- IPO
- 1998
- Employees
- 4
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on ATMS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $55.79M
- P/E
- -49.80
- PEG
- 0.15
- P/S
- 179.40
- P/B
- -27694.96
- EV/EBITDA
- -41.77
- Div Yield
- 0.00%
- Gross Margin
- 82.64%
- Op Margin
- -436.98%
- Net Margin
- -434.41%
- ROE
- 177.53%
- ROIC
- 213.72%
Latest fiscal year · YoY change
- Revenue
- $311.00K+0.0%
- Gross Profit
- $257.00K+0.0%
- Op Income
- $-1,359,000
- Net Income
- $-1,351,000-650.6%
- EPS
- $-0.01-44.9%
- OCF Growth
- -434.2%
- FCF Growth
- -469.9%
- 52W High
- $4.50
- 52W Low
- $0.11
- 50D MA
- $0.48
- 200D MA
- $1.25
- Beta
- 0.00
- RSI (14)
- 45
- Avg Volume
- 1.53K
No earnings-call transcripts are available for ATMS yet.
- Free Float
- 0.0%
- Shares Outstanding
- 112.03M
- Float Shares
- 0
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 22 | CITRON SHIMON | other | 0 |
| Jun 30, 22 | CITRON SHIMON | other | 0 |
| Jun 30, 22 | CITRON SHIMON | other | 0 |
| Jun 30, 22 | CITRON SHIMON | other | 0 |
| Jul 26, 22 | Dana David | other | 0 |
| Dec 18, 18 | Peleg Gadi | sell | 182 |
| Mar 15, 18 | Culley Brian M | other | 48,528 |
| Mar 15, 18 | Morris Chanan | other | 50,000 |
| Oct 23, 17 | Culley Brian M | buy | 25,000 |
| Oct 23, 17 | Culley Brian M | buy | 12,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ATMS coverage
Recent articles, reports, and earnings notes.
No research on ATMS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ATMS report →